SAGE Therapeutics (SAGE)

SAGE Therapeutics (SAGE) Financial Statements


SAGE Therapeutics Financial Overview

SAGE Therapeutics's market cap is currently ―. The company's EPS TTM is $-9.926; its P/E ratio is -2.07; SAGE Therapeutics is scheduled to report earnings on November 7, 2023, and the estimated EPS forecast is $-2.65. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue$ 2.46M$ 3.29M$ 2.86M$ 1.74M$ 1.50M
Gross Profit$ 2.47M$ 3.29M$ 2.86M$ 1.55M$ 1.30M
EBIT$ -159.91M$ -155.66M$ -153.94M$ -141.48M$ -128.41M
EBITDA$ -159.58M$ -155.34M$ -153.67M$ -141.20M$ -128.13M
Net Income Common Stockholders$ -160.32M$ -146.83M$ -147.15M$ -137.32M$ -126.26M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.00B$ 1.13B$ 1.27B$ 1.39B$ 1.51B
Total Assets$ 1.08B$ 1.22B$ 1.35B$ 1.49B$ 1.60B
Total Debt$ 8.73M$ 10.45M$ 12.13M$ 13.77M$ 15.36M
Net Debt$ -993.89M$ -1.12B$ -1.26B$ -1.38B$ -1.50B
Total Liabilities$ 97.91M$ 87.56M$ 1.38B$ 105.95M$ 97.14M
Stockholders Equity$ 984.38M$ 1.13B$ 1.28B$ 1.38B$ 1.50B
Cash Flow-
Free Cash Flow$ -131.63M$ -153.91M$ -127.24M$ -119.23M$ -106.56M
Operating Cash Flow$ -131.52M$ -153.68M$ -126.95M$ -118.86M$ -106.44M
Investing Cash Flow$ 45.59M$ 194.87M$ 89.78M$ 110.95M$ 134.26M
Financing Cash Flow$ 847.00K$ 2.67M$ 29.00K$ 1.23M$ 13.00K
Currency in USD

SAGE Therapeutics Earnings and Revenue History

SAGE Therapeutics Debt to Assets

SAGE Therapeutics Cash Flow

SAGE Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis